Four Democratic U.S. senators sent a letter on Monday to Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., questioning whether his recent public statements regarding a financial stake in vaccine litigation contradict his previous ethics disclosures. The lawmakers stated that Kennedy's current account of how he handled his interest in a $50 million settlement involving Merck’s Gardasil vaccine does not match the written testimony and federal ethics filings he provided during his confirmation process last year.
The inquiry centers on legal fees stemming from litigation against Merck over its Gardasil vaccine, which is used to prevent cancers caused by the human papillomavirus (HPV). Before becoming HHS secretary, Kennedy served as an attorney in several cases against the company. This year, Merck agreed to pay $50 million to resolve that litigation, raising questions from lawmakers about who received Kennedy's share of the legal fees, as he now oversees the agencies that regulate such products.
During his confirmation, Kennedy initially planned to retain a 10% fee from Gardasil cases referred to the Wisner Baum law firm. After Sen. Elizabeth Warren (D-MA) and others raised concerns, Kennedy stated in ethics filings and testimony to the Senate Finance Committee that he would transfer his interest to one of his sons. However, in a social media post earlier this month, Kennedy stated he "relinquished any interest" back to the law firm before taking office and said that neither he nor his family received any money from the settlement. He also accused Sen. Warren and media outlets of spreading lies to discredit his work.
A person following this would notice potential shifts in how federal health agencies, such as the Food and Drug Administration (FDA) or the Centers for Disease Control and Prevention (CDC), handle vaccine recommendations and approvals. For example, the CDC recently attempted to reduce the recommended dosage for the HPV vaccine, a move that was subsequently blocked by a federal judge. If ethics agreements are modified without updated filings, it could change how oversight committees monitor for conflicts of interest in decisions that affect the availability and cost of routine immunizations for millions of American children.
The outcome of this inquiry may set a precedent for how the executive branch handles the disposal of private legal interests and the accuracy of sworn testimony provided to Congress. If the Senate Finance Committee finds that federal ethics filings were not updated to reflect the actual disposition of assets, it could lead to further investigations into the secretary's compliance with government standards. As of Monday, an HHS spokesperson had not provided a new comment, and the senators are awaiting an explanation for why Kennedy's ethics forms certified a transfer to a family member that he now says did not occur.
What happens next depends on the secretary's response to the Monday letter. Lawmakers are seeking clarification on why subsequent filings did not reflect his recent public statements. There are currently no public deadlines for a response or scheduled committee votes, but the inquiry remains an active matter for the U.S. Senate.